|
KMID : 1144320210530010166
|
|
감염과 화학요법
2021 Volume.53 No. 1 p.166 ~ p.219
|
|
|
Revised Korean Society of Infectious Diseases/National Evidence-based Healthcarea Collaborating Agency Guidelines on the Treatment of Patients with COVID-19
|
|
Kim Sun-Bean
Ryoo Seung-Eun
Huh Kyung-Min
Joo Eun-Jeong
Kim Youn-Jeong
Choi Won-Suk
Kim Yae-Jean
Yoon Young-Kyung
Heo Jung-Yeon
Seo Yu-Bin
Jeong Su-Jin
Park Dong-Ah
Yu Su-Yeon
Lee Hyeon-Jeong
Kim Ji-Min
Jin Yan
Park Jung-Eun
Peck Kyong-Ran
Choi Mi-Young
Yeom Joon-Sup
|
|
|
Abstract
|
|
|
|
Despite the global effort to mitigate the spread, coronavirus disease 2019 (COVID-19) has become a pandemic that took more than 2 million lives. There are numerous ongoing clinical studies aiming to find treatment options and many are being published daily. Some effective treatment options, albeit of variable efficacy, have been discovered. Therefore, it is necessary to develop an evidence-based methodology, to continuously check for new evidence, and to update recommendations accordingly. Here we provide guidelines on pharmaceutical treatment for COVID-19 based on the latest evidence.
|
|
|
KEYWORD
|
|
|
COVID-19, Clinical practice guidelines, Korea
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|